The Effects of Viral Load Burden on Pregnancy Loss among HIV-Infected Women in the United States
Table 3
Sensitivity analyses; adjusted risk ratios for a one-unit increase in exposure.
Sensitivity analysis description
aRR (95% CI)
Most recent VL
Viremia since ART
Viremia in two years
Original
1.17 (1.01, 1.35)
0.80 (0.69, 0.92)
1.00 (0.90, 1.11)
Restricted to exposure after 1998 and adjusted for HAART
1.27 (1.07, 1.50)
0.99 (0.82, 1.17)
0.97 (0.83, 1.13)
Dropped VL at ART initiation
N/A
0.83 (0.68, 1.03)
N/A
Adjusted for time on ART
N/A
0.80 (0.68, 0.95)
N/A
Only included VL during pregnancy
1.10 (0.87, 1.39)
N/A
N/A
Time frame changed to one year
N/A
N/A
0.87 (0.75, 1.00)
Time frame changed to three years
N/A
N/A
0.97 (0.87, 1.09)
Excluded stillbirths
1.18 (1.01, 1.38)
0.80 (0.69, 0.93)
0.99 (0.88, 1.12)
Modification by CD4
CD4 ≤ 500
1.15 (0.99, 1.33)
0.81 (0.68, 0.97)
0.94 (0.82, 1.07)
CD4 > 500
1.17 (0.95, 1.43)
0.81 (0.67, 0.98)
1.16 (0.98, 1.36)
Adjusted for CD4 nadir
1.18 (1.03, 1.35)
0.79 (0.69, 0.91)
1.02 (0.91, 1.14)
aRR = adjusted risk ratio, ART = antiretroviral therapy, HAART = highly active antiretroviral therapy, and VL = viral load. Adjusted for maternal age (with a linear spline at age 35), race, income, prior pregnancy loss, smoking, noninjection drug use, CD4 count at baseline, and ART use at baseline (separately controlling for mono-/dual and HAART versus none).
